Table 4.
Characteristics of the initial irAEs and clinical courses, related treatment interruption.
| Anti-PD-1 treatment interruption (n = 52) | Anti-PD-1 treatment continuation (n = 32) | p-value | ||
|---|---|---|---|---|
| Phenotypes of irAE | Pneumonitis, n (%) | 29 (54) | 1 (3) | <0.001a |
| Diarrhea, n (%) | 3 (6) | 5 (16) | 0.25a | |
| Adrenal insufficiency, n (%) | 3 (6) | 3 (9) | 0.67a | |
| Infusion reaction, n (%) | 3 (6) | 3 (9) | 0.67a | |
| Thyroid dysfunction, n (%) | 9 (17) | 14 (44) | 0.017b | |
| Pyrexia, n (%) | 5 (10) | 5 (15) | 0.50a | |
| Rash, n (%) | 7 (13) | 6 (19) | 0.73b | |
| CTCAE grade ≥3, n (%) | 20 (38) | 0 (0) | <0.001a | |
| Median duration between initial anti-PD-1 treatment to the first irAE onset, days (range) | 40 (0–522) |
60 (0–384) |
1c | |
| ORR, n (%) | 24 (46) | 21 (66) | 0.13b | |
| DCR, n (%) | 36 (69) | 27 (84) | 0.19b | |
Differences between groups were identified using aFisher’s exact test, bchi-square test, or cStudent’s t-test. IrAE, immune-related adverse event; CTCAE, Common Terminology Criteria for Adverse Events; PD-1, programmed cell death-1; ORR, overall response rate; DCR, disease control rate.